Search - tctmd.com

Displaying 1 - 20 of 83

Sort: Relevancy | Date

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

Presentation TCT 2025

TCT 467: Comparative Long-Term Outcomes Of Sirolimus vs Paclitaxel-Coated Balloons In STEMI: A Retrospective Analysis

Presenter: Bhagya Harindi Loku Waduge

October 27, 2025

Presentation TCT 2025

TCT 469: Comparative Outcomes of Sirolimus versus Paclitaxel-Coated Balloon Angioplasty in De Novo Coronary Lesions: Real-World Data

Presenter: Bhagya Harindi Loku Waduge

October 27, 2025

Presentation TCT 2025

TCT 515: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

TCT 510: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

TCT 511: Paclitaxel-Coated Balloons versus Newer-Generation Drug-Eluting Stents for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Controlled Trials

Presenter: Kamil Bujak

October 27, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Presentation TCT 2025

Two-year Outcome of Sirolimus-coated Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: Evidence from the Randomized SIRONA Trial

Presenter: Ulf Teichgräber

October 26, 2025

Presentation TCT 2025

TCT 178: Use of the AGENT Paclitaxel-Coated Balloon in the United States Shortly After FDA Approval: Early Results from the AGENT Post-Approval Study

Presenter: Christina Lalani

October 26, 2025

Presentation TCT 2025

TCT 180: Paclitaxel-Coated Balloon versus Uncoated Balloon for Coronary In-Stent Restenosis in Patients with Acute Coronary Syndromes: A Subanalysis of the AGENT IDE Trial

Presenter: Neal S. Kleiman

October 26, 2025

Presentation TCT 2025

TCT 182: Impact of Lesion Preparation Strategy on the Efficacy of Paclitaxel Coated Balloon for Coronary In-stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Aditya Mantha

October 26, 2025

Presentation TCT 2025

TCT 181: Efficacy and Safety of Coronary Angioplasty Using a Paclitaxel-Coated vs Uncoated Balloon in Patients with In-Stent Restenosis Stratified by Restenosis Risk: A Subanalysis of the AGENT IDE

Presenter: Prakriti Gaba

October 26, 2025

Presentation TCT 2024

Sirolimus- vs. Paclitaxel-Coated Balloons for the Treatment?of Coronary Artery Disease

Presenter: Pier Pasquale Leone

October 30, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

Presentation TCT 2024

TCT 500: Long-term Outcomes and Predictor of Target Lesion Revascularization the Patients After Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

Presenter: Ikuta Akihiro

October 29, 2024

Presentation TCT 2024

TCT 501: Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Presenter: Dealla Samadi

October 29, 2024

Presentation TCT 2024

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

Presenter: Ulf Teichgräber

October 29, 2024

Presentation TCT 2024

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Jennifer Tremmel

October 29, 2024

Presentation TCT 2024

TCT 700: Drug-Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons

Presenter: Linnea Tscheuschner

October 29, 2024

Presentation TCT 2024

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

Presenter: Akihiro Tobe

October 29, 2024

Advertisement

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

TCT 467: Comparative Long-Term Outcomes Of Sirolimus vs Paclitaxel-Coated Balloons In STEMI: A Retrospective Analysis

TCT 469: Comparative Outcomes of Sirolimus versus Paclitaxel-Coated Balloon Angioplasty in De Novo Coronary Lesions: Real-World Data

TCT 515: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

TCT 510: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

TCT 511: Paclitaxel-Coated Balloons versus Newer-Generation Drug-Eluting Stents for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Controlled Trials

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Two-year Outcome of Sirolimus-coated Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: Evidence from the Randomized SIRONA Trial

TCT 178: Use of the AGENT Paclitaxel-Coated Balloon in the United States Shortly After FDA Approval: Early Results from the AGENT Post-Approval Study

TCT 180: Paclitaxel-Coated Balloon versus Uncoated Balloon for Coronary In-Stent Restenosis in Patients with Acute Coronary Syndromes: A Subanalysis of the AGENT IDE Trial

TCT 182: Impact of Lesion Preparation Strategy on the Efficacy of Paclitaxel Coated Balloon for Coronary In-stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 181: Efficacy and Safety of Coronary Angioplasty Using a Paclitaxel-Coated vs Uncoated Balloon in Patients with In-Stent Restenosis Stratified by Restenosis Risk: A Subanalysis of the AGENT IDE

Sirolimus- vs. Paclitaxel-Coated Balloons for the Treatment?of Coronary Artery Disease

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

TCT 500: Long-term Outcomes and Predictor of Target Lesion Revascularization the Patients After Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

TCT 501: Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 700: Drug-Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content